Metabolic syndrome

Metabolic syndrome
OMIM	605552
MedlinePlus	0072903
MeSH	D024821

The metabolic syndrome, also known as the dysmetabolic syndrome, metabolic syndrome X, or insulin resistance syndrome, is defined as "a cluster of metabolic risk factors for cardiovascular diseases and type 2 diabetes mellitus. The main components of metabolic syndrome X include excess abdominal fat; atherogenic dyslipidemia; hypertension; hyperglycemia; insulin resistance; a proinflammatory state; and a prothrombotic (thrombosis) state."

The metabolic syndrome is a major public health concern worldwide as a particularly serious consequence of the global obesity epidemic , but the metabolic syndrome can be present in the absence of frank obesity. Almost one fourth of Americans have metabolic syndrome, and the proportion keeps raising.

The metabolic syndrome is a serious disturbance of body metabolism and physiology, consisting of resistance of certain cell types of the body to the ability of the hormone insulin to promote the entry into cells of the energy-rich molecule, glucose, and two or more of the following abnormalities: high blood pressure (or use of drugs to control hypertension); high levels of serum triglycerides; low levels of high-density lipoprotein (HDL) cholesterol; overweight; detectable levels of the protein albumin in the urine (microalbuminuria). The abnormalities of triglyceride levels typically associate with other blood fat disturbances (dyslipidemia) that foster atherosclerosis (the buildup of plaques in artery walls that can lead to reduced blood flow to vital organs, including the heart) and to formation of blood clots that can break off and clog vital vessels to the brain, causing stroke. The biochemical factors that promote clot formation are also stimulated in the metabolic syndrome, and the syndrome appears to be one of a chronic state of inflammation, the typical body response to tissue injury.

Metabolic syndrome (MS) is a constellation of metabolic derangements associated with vascular endothelial dysfunction and oxidative stress and is widely regarded as an inflammatory condition, accompanied by an increased risk for cardiovascular disease. Diagnostic criteria There are different clinical definitions of the metabolic syndrome; because of disagreement about the relative importance of insulin resistance in the cluster of risk factors, two definitions do not involve this risk factor. It is defined by the World Health Organisation using the following criteria: Insulin resistance, identified by one of the following: Type 2 diabetes Impaired fasting glucose Impaired glucose tolerance or, for those with normal fasting glucose levels (<110mg/dL), glucose uptake below the lowest quartile for background population under investigation under hyperinsulinemic, euglycemic conditions in conjunction with any two of the following: Antihypertensive medication and/or high blood pressure (≥140mmHg systolic or ≥90mmHg diastolic) Plasma triglycerides ≥150mg/dL (≥1.7mmol/L) HDL cholesterol <35mg/dL (0.9mmol/L) in men or <39mg/dL (1.0mmol/L) in women BMI (Body Mass Index) >30kg/m² and/or waist:hip ratio >0.9 in men, >0.85 in women Urinary albumin excretion rate ≥20μmg/g or albumin: creatinine ratio ≥30 mg/g. Risk factors for developing metabolic syndrome Suboptimal dietary potassium Study #1 In a cros-sectional study of a representative sample of the U.S. population (>25,000 participants analyzed), Sharma and colleagues concluded: "Low dietary potassium intake is associated with an increased risk of metabolic syndrome in US adults'." The study merely identifies an association of low dietary potassium in adults meeting the diagnostic criteria of metabolic syndrome. The association analysis suggested an increased risk of metabolic syndrome of 35% for those with metabolic syndrome consuming 44 mmol/day [1701 mg/day] or less, when compared to those consuming 84 mmol/day [3290 mg/day] or more. The recommended intake of potassium for adult Americans: 120 mmol/day [4700 mg/day]. Accordingly, we do not know what the relative risk of metabolic syndrome when the lower potassium intakes compare with intakes greater than 120 mmol/day, nor from the associational study, whether some type of interventional study that raised potassium intake to >120 mmol/day could prevent or mitigate the metabolic syndrome. Study #2 In a somewhat similar study, based on the Korean National Health and Nutritional Examination Survey data from 2008 to 2010 (>19,000 participants), Lee and colleagues concluded: "Our findings suggest that higher potassium intake is significantly associated with lower risk of MS [metabolic syndrome in women of general population and IR [insulin resistance] is thought to be participated in the relationship." They added: "These results support the recommendations for higher consumption of potassium rich foods to prevent cardiovascular diseases in another aspect." Psychological components An interesting but yet underdeveloped aspect of research on the metabolic syndrome relates to the syndrome's psychological components. 'Cynical hostility' appears to predict the metabolic syndrome, which in turn predicts cardiovascular disease. Worthy of note, in a study, only high hostility and low HDL cholesterol predicted coronary heart disease. At present, there is no agreement on the nature of the relationship between hostility and the metabolic syndrome. Consequences of the metabolic syndrome Diabetic complications and cardiovascular diseases The metabolic syndrome is thus a cluster of risk factors for diabetes complications and cardiovascular diseases. The syndrome includes proinflammatory and prothrombotic features. Other consequences The metabolic syndrome could also promote the development of cancer, polycystic ovary syndrome (PCOS), and nonalcoholic fatty liver disease". Chronic kidney disease Studies have established an association of metabolic syndrome and new occurrences of chronic kidney disease. Recently investigators have examined whether metabolic syndrome associates with all-cause mortality and end-stage renal disease, in patients with advanced (stages 3 & 4) kidney disease. They concluded: Presence of MetS [metabolic syndrome] in younger stage 3 and stage 4 CKD [chronic kidney disease] patients are associated with all-cause mortality and ESRD [end-stage renal disease]. The associations between individual components of MetS and the composite end-point seem to vary with diabetes and dyslipidemia having pronounced associations. Cancer A number of components of the metabolic syndrome (MS) are likely to contribute, especially in combination, to cause cancer. While the MS-colon cancer is the most convincing link, other epidemiologic studies investigating the link of MS with other cancers are awaited. References